Exploiting viral natural history for vaccine development

The partial successes of the Phase 2 gB-based vaccine trials for HCMV highlight the very real likelihood that vaccine-mediated induction of antibodies that neutralize the fusion pathway of fibroblast infection is not sufficient as a singular strategy to confer protective efficacy against primary HCM...

Descripción completa

Detalles Bibliográficos
Autor principal: Barry, Peter A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2015
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439440/
https://www.ncbi.nlm.nih.gov/pubmed/25794555
http://dx.doi.org/10.1007/s00430-015-0406-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439440/
https://www.ncbi.nlm.nih.gov/pubmed/25794555
http://dx.doi.org/10.1007/s00430-015-0406-1

Ejemplares similares